Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL

Our previous clinical study achieved complete remission (CR) rates of >90% following chimeric antigen receptor T cells targeting CD19 (CART19) treatment of refractory/relapsed B cell acute lymphoblastic leukemia (r/r B-ALL); however, the influence of the leukemia burden in peripheral blood (PB) b...

Full description

Saved in:
Bibliographic Details
Main Authors: Biping Deng, Jing Pan, Zhaoli Liu, Shuangyou Liu, Yunlong Chen, Xiaomin Qu, Yu'e Zhang, Yuehui Lin, Yanlei Zhang, Xinjian Yu, Zhongxin Zhang, Xuansha Niu, Rong Luan, Ming Ma, Xiaomei Li, Tingting Liu, Xi'ai Wu, Huan Niu, Alex H. Chang, Chunrong Tong
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
CAR-T cells
CART19
B-cell acute lymphoblastic leukemia
PB blasts
leukemia burden in peripheral blood
time of apheresis
Genetics
QH426-470
Cytology
QH573-671
Online Access:https://doaj.org/article/8a5d1e95aae845aaab269d3ee1c2bab7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/8a5d1e95aae845aaab269d3ee1c2bab7

Similar Items